Copyright © Inderes 2011 - present. All rights reserved.

Faron Pharmaceuticals

1.98 EUR

-1.10 %

5,528 following

FARON

First North Finland

Biotechnology & Pharmaceuticals

Health Care

-1.10 %
-17.75 %
-7.57 %
-27.55 %
-22.13 %
-3.98 %
-53.02 %
-37.99 %
-43.16 %

Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.

Read more
Market cap
234.52M EUR
Turnover
462.38K EUR
P/E (adj.) (25e)
-8.97
EV/EBIT (adj.) (25e)
-10.32
P/B (25e)
-27.19
EV/S (25e)
58,359.08
Dividend yield-% (25e)
-
Coverage
Recommendation
Accumulate
Target price
2.50 EUR
Updated
2025-10-24
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 2025-10-24

Latest extensive report

Released: 2022-08-23

Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
4/3
2026

Annual report '25

30/3
2026

General meeting '26

26/8
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
Lest there be a misunderstanding, this interpretation is false concerning the TP53 mutation. Furthermore, your interpretation only applies to HR MDS wt patients. In addition, your interpretation focuses on CR.
6 hours ago
by RipaRapa
13
So all 700 biotechs report more clearly? And Zeidan reported results that are the same as with just aza… oh come on.
6 hours ago
by JJ
10
In 1st line, 7 patients had Baseline TD. 4 1st line and 3 r/r patients achieved a TD-TI response during treatment. These 4 are not part of that group of 7 baseline TD patients! The announcement is factually incorrect. No wonder the poster has been removed. Quickly save it from the...
3 hours ago
by Clark kent
4
https://ashpublications.org/blood/article/doi/10.1182/blood.2025029727/548015/The-conundrum-of-drug-development-in-higher-risk I won’t bother, I’ll just quote smarter people. Here’s a recent publication by our esteemed Professor Zeidan. It costs a hundred. At the end, a tabulation...
5 hours ago
by Clark kent
3
Starting from 2min50sec in the video, some very interesting information about first-line responses is heard. According to what I heard, the first-line composite CR responses were 55% and CR responses were 30% according to IWG2023 criteria. A moment after that, it is stated that the...
7 hours ago
3
WOW. It was good that this figure was looked at more closely. The 57% figure is on-treatment TD-TI, not baseline TD-TI. Medically, these are completely different things. Look at the wording of the poster, the swimlanes. This explains the difference from the publication and the abstract...
3 hours ago
by Clark kent
2
I understand. From some Faron material, I had already inferred that NGS would have been used. I interpret that old samples have been dug up for more detailed analysis and then TP53m was found.
7 hours ago
by RipaRapa
2
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.